Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBIT (2016 - 2025)

CorMedix has reported EBIT over the past 16 years, most recently at -$59.5 million for Q4 2025.

  • Quarterly results put EBIT at -$59.5 million for Q4 2025, down 290.53% from a year ago — trailing twelve months through Dec 2025 was $31.5 million (up 876.32% YoY), and the annual figure for FY2025 was $31.5 million, up 876.32%.
  • EBIT reached -$59.5 million in Q4 2025 per CRMD's latest filing, down from $51.3 million in the prior quarter.
  • Across five years, EBIT topped out at $51.3 million in Q3 2025 and bottomed at -$59.5 million in Q4 2025.
  • Median EBIT over the past 5 years was -$8.0 million (2021), compared with a mean of -$4.1 million.
  • Peak annual rise in EBIT hit 1661.93% in 2025, while the deepest fall reached 290.53% in 2025.
  • Over 5 years, EBIT stood at -$7.8 million in 2021, then decreased by 7.83% to -$8.4 million in 2022, then crashed by 86.77% to -$15.7 million in 2023, then skyrocketed by 299.34% to $31.2 million in 2024, then crashed by 290.53% to -$59.5 million in 2025.
  • Business Quant data shows EBIT for CRMD at -$59.5 million in Q4 2025, $51.3 million in Q3 2025, and $19.5 million in Q2 2025.